18575 Jamboree Road
Suite 275-S
Irvine, CA 92612
United States
858 283 0280
https://reneopharma.com
Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 8
Name | Titel | Zahlen | Ausgeübt | Geburtsjahr |
---|---|---|---|---|
Mr. Michael G. Grey | Founder & Executive Chairman | 100k | N/A | 1953 |
Mr. Gregory J. Flesher | President, CEO & Director | 569,7k | N/A | 1970 |
Dr. Alejandro Dorenbaum M.D. | Chief Medical Officer | 466,23k | N/A | 1961 |
Ms. Ashley F. Hall J.D. | Chief Development Officer | 447,1k | N/A | 1972 |
Ms. Jennifer P. Lam | SVP of Finance & Administration and Principal Financial & Accounting Officer | N/A | N/A | N/A |
Mr. Michael P. Cruse | Chief Operating Officer | 535,47k | N/A | 1972 |
Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. The company's lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Irvine, California.
Reneo Pharmaceuticals, Inc.s ISS Governance QualityScore, Stand 1. Juni 2024, lautet 9. Die grundlegenden Scores sind Audit: 9, Vorstand: 10, Shareholderrechte: 8, Kompensation: 9.